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Javed Mohammed1, Andrew J. Gunderson1, Hong-Hanh Khong1, Richard D. Koubek1, Mark C. Udey2 and
Adam B. Glick1
Overexpression of transforming growth factor beta-1 (TGFb1) in mouse epidermis causes cutaneous
inflammation and keratinocyte hyperproliferation. Here we examined acute effects of TGFb1 overproduction
by keratinocytes on skin dendritic cells (DCs). TGFb1 induction for 2 and 4 days increased the numbers
and CD86 expression of B220þ plasmacytoid DCs (pDCs) and CD207þCD103þ , CD207CD103CD11bþ ,
and CD207CD103CD11b dermal DCs (dDCs) in skin-draining lymph nodes (SDLNs). The dermis of TGFb1-
overexpressing mice had significantly more pDCs, CD207þCD103þ dDCs, and CD207CD11bþ dDCs in the
absence of increased dermal proliferation. Application of dye, tetramethyl rhodamine iso-thiocyanate (TRITC),
in dibutylpthalate (DBP) solution after TGFb1 induction increased the numbers of TRITCþCD207 dDCs in
SDLNs, and augmented TRITC/DBP-induced Langerhans cell (LC) migration 72hours post TRITC treatment.
Consistent with this, LC migration was increased in vitro by TGFb1 overexpression in skin explants and by
exogenous TGFb1 in culture media. Transient TGFb1 induction during DNFB sensitization increased contact
hypersensitivity responses by 1.5-fold. Thus, elevated epidermal TGFb1 alone is sufficient to alter homeostasis
of multiple cutaneous DC subsets, and enhance DC migration and immune responses to contact sensitizers.
These results highlight a role for keratinocyte-derived TGFb1 in DC trafficking and in the initiation of skin
inflammation.
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INTRODUCTION
Skin contains a dense network of dendritic cells (DCs) that are
initiators of a wide range of immune responses and act by
bridging innate and adaptive immunity while maintaining
tissue homeostasis in steady state (Steinman, 1991). Langer-
hans cells (LCs), which are radio-resistant, self-renewing, and
characterized by the expression of langerin (CD207), are the
primary DC subset in the epidermis of healthy skin (Ginhoux
and Merad, 2010). The dermis contains DC subsets broadly
classified as CD207þCD103þ and CD207CD103, with
the latter subset further subdivided on the basis of CD11b and
other markers (Merad et al., 2008; Henri et al., 2010). Skin
DCs acquire and process exogenous antigens, undergo
maturation, and migrate to skin-draining lymph nodes
(SDLNs) where they induce the activation of naive T cells
(Banchereau and Steinman, 1998).
Transforming growth factor beta-1 (TGFb1) is one of the
major regulators of DC biology in the skin. In vitro studies
show that TGFb1 is important for promoting LC differentia-
tion from a CD34þ promonocyte bone marrow precursor
(Strobl and Knapp, 1999), whereas for both LCs and other DCs,
TGFb1 inhibits activation, maturation, and immunogenicity
and promotes tolerogenic function (Geissmann et al., 1999;
Fainaru et al., 2007; Ohtani et al., 2009; Torres-Aguilar et al.,
2010). In vivo studies have demonstrated a critical require-
ment of both autocrine and paracrine TGFb1 signaling for LC
development and epidermal residency (Borkowski et al., 1996,
1997; Kaplan et al., 2007; Kel et al., 2010; Zahner et al., 2011).
However, homeostasis and numbers of CD207þCD103þ
dermal DC (dDC) appear to be unaffected in mice with a
deletion of the TGFb1 type-1 receptor in all CD207þ DCs
(Kel et al., 2010; Zahner et al., 2011) and in Tgfb1/
mice (Nagao et al., 2009). In contrast, for CD207CD103
dDCs and for DCs that infiltrate the skin under infla-
mmatory states, there is little information on the in vivo role
of TGFb1.
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Significant increases in epidermal and skin TGFb1 levels
occur in response to inflammatory stimuli (Akhurst et al.,
1988), following wounding (Kane et al., 1991; Levine et al.,
1993; Wang et al., 2006), in chronic skin diseases such as
psoriasis (Kane et al., 1990; Flisiak et al., 2002, 2003) and in
premalignant keratinocytes (Glick et al., 1991). Previous
studies have shown that long-term overexpression of active or
latent TGFb1 in mouse epidermis causes a chronic inflam-
matory phenotype associated with keratinocyte hyperproli-
feration and T-cell infiltration (Liu et al., 2001; Li et al., 2004;
Han et al., 2010). However, recent studies have suggested
that the TGFb1-induced inflammation is not solely dependent
on T cells (Michaelis et al., 2010), or the interleukin 17/
interleukin 23 axis (Fitch et al., 2009), indicating involvement
of additional pathways or immune cells.
We previously showed that induction of TGFb1 in
papillomas caused a rapid increase in tumor-infiltrating
macrophages and DCs, and an increase in the numbers of
CD11cþ and CD11bþ cells in SDLNs (Mohammed et al.,
2010), suggesting that tissue inflammation and migration of
DCs may be a primary response to elevated TGFb1 levels.
Here we show that induction of active TGFb1 in the basal
layer of mouse epidermis causes significant and rapid
changes in cutaneous DC migration and influx, and enhances
contact hypersensitivity (CHS) responses. These results
provide insight into the role of keratinocyte-derived TGFb1
in skin DC homeostasis and in the initiation of skin
inflammation.
RESULTS
Elevated keratinocyte TGFb1 increases DC numbers in SDLNs
To determine the effect of elevated epidermal TGFb1 levels
on cutaneous DC populations, we placed 7-week-old double
transgenic (DT) (K14rTAxtetOTGFb1) mice on doxycycline
(Dox) chow to induce active TGFb1 in keratinocytes and then
analyzed migratory DC subset accumulation in the SDLNs.
We gated on MHCIIhi lymph node (LN) cells to identify DCs
migrating from the skin and excluded any LN-resident
CD8þCD103þCD207þ DCs that are MHCIIint (Dakic
et al., 2004; Kissenpfennig et al., 2005). We identified
five skin-derived DC subsets in the SDLNs of FVB/n mice
(Figure 1a) similar to those in C57BL/6 mice (Henri et al.,
2010): B220þ plasmacytoid DCs (pDCs), CD207þCD103
(LC), CD207þCD103þdDCs, and CD207CD103dDCs,
which are either CD11bþ or CD11b (referred to as
CD207CD11bþ dDCs and CD207CD11b dDCs, res-
pectively). At steady state, CD207þ dDCs constituted the
highest percentage of DCs in the LN (36%). Two days after
induction of TGFb1 expression in keratinocytes, there was
a significant expansion of the CD207CD11b subset
relative to the other DCs, and this persisted through 4 days
(Figure 1b). The percentage of pDCs also increased after
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Figure 1. Elevated keratinocyte transforming growth factor beta-1 alters migratory dendritic cell (DC) percentages and numbers. Double transgenic (DT) mice
were given regular or doxycycline (Dox) chow (1 g kg1) for 2 or 4 days and skin-draining lymph nodes (LNs) were harvested for immunophenotypic analysis of
MHCIIhi cells. (a) Gating strategy to identify B220þ plasmacytoid DCs, Langerhans cell, CD207þ , and CD207 dermal DC subsets. (b) Analysis of five DC
subsets identified in a for their percentages following 2 and 4 days of Dox treatment. In addition, tetramethyl rhodamine iso-thiocyanate (TRITC)þ DC
percentages were analyzed 24 hours following TRITC painting in a 1:1 solution of acetone and dibutylpthalate. (c) Analysis of five DC subsets identified in a for
their numbers following 2 and 4 days of Dox treatment (N¼ 4–8, repeated at least twice with similar results). Error bars¼±SEM.
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4 days of TGFb1 induction. The alteration in skin-derived DC
percentages in SDLNs at 2 and 4 days after induction was
similar to tetramethyl rhodamine iso-thiocyanate (TRITC)þ
DC subsets 24 hours post TRITC/dibutylpthalate (DBP) appli-
cation (Figure 1b), confirming their skin origin and suggesting
that the effects of TGFb1 overexpression and the irritant DBP
on skin CD11b dDCs were similar. There was also a 4–5-
fold increase in absolute numbers of CD207CD11b DCs
at 2 days, which increased to 11-fold relative to steady state
at 4 days, a 2-fold increase in the number of CD207þ
CD103þ dDCs, a 3-fold increase in CD207CD11bþ DCs,
and a 4-fold increase in B220þ pDCs in the SDLNs at 4 days
post TGFb1 induction (Figure 1c and d). Thus, TGFb1 appears
to mobilize primarily CD207CD11b dDCs but not LCs,
although other DC subsets are significantly affected.
Keratinocyte TGFb1 causes selective influx and proliferation of
DCs in the dermis
To further examine TGFb1-induced changes in cutaneous DC
homeostasis, we analyzed the percentage of MHCIIþ cells in
the dermis. Two days post TGFb1 induction, there was a
significant increase in the frequency of MHCIIþ cells in the
dermis, which remained high through 4 days (Figure 2a). The
increase in MHCIIþ cells was primarily due to an increase in
B220þ pDCs (Figure 2b and c). In addition, 4 days after
TGFb1 induction, there was a 2.5-fold higher percentage of
CD207þ103þ and CD207CD11bþ dDCs (Figure 2c).
To test whether TGFb1 induction altered proliferation of
resident skin DC subsets, we injected mice with 1.5mg
bromodeoxyuridine (BrdU) 3 hours before necropsy follow-
ing 2 days of TGFb1 induction and determined the
percentage of BrdU-positive cells within individual dDC
subsets by flow cytometry. Although significantly more
MHCIIþ and B220þ pDCs were noted in the dermis, no
changes in BrdU incorporation in any of the DC subsets was
detected (Figure 3a). Alternatively, we dosed mice continu-
ously with BrdU while inducing TGFb1 at the same time for 4
days. There was a two- and three-fold increase in BrdU
labeling in CD207þCD103þ and CD207CD11b dDCs,
respectively, but no difference in other DC subsets including
pDCs (Figure 3b). Thus, TGFb1 causes an increase of pDCs in
the dermis without affecting proliferation and selectively
promotes proliferation of other dDC subsets.
CD86 expression of skin-derived DC subsets is increased in
SDLNs but not in the dermis
Consistent with increases in the numbers of skin-derived DC
subsets in SDLNs, MHCIIþ cells in dermal sheets were
detected in numerous distinct dermal cords, a characteristic
feature of DCs aligning in the dermal lymphatics before
migration, following 4 days of TGFb1 induction (Figure 4a).
DCs upregulate CD86 levels upon maturation by antigen
encounter and/or inflammatory cytokines, which is linked to
their migration to SDLNs (Banchereau and Steinman, 1998).
We evaluated dDC subsets and their counterparts in SDLN
for CD86 expression following TGFb1 induction. In steady-
state dermis, CD207þCD103þ dDCs had the highest and
CD207CD11b dDCs had the lowest CD86 levels. TGFb1
caused a significant increase in CD86 expression only in the
CD207CD11b dDC subset at day 2 and no change in
CD86 could be detected in any subset at day 4 (Figure 4b
and c). However, there was an increase in CD86 expression
in the SDLNs of all of the skin-derived DC subsets (Figure 4d),
with the greatest increase occurring in the CD207CD11bþ
and CD207CD11b dDC subsets (2.8- and 4.8-fold,
respectively), and this was sustained through day 4 post
TGFb1 induction (data not shown). Supplementary Figure S1
online shows representative histograms for CD86 expression
on dDC subsets in the dermis and SDLNs.
Keratinocyte TGFb1 enhances DC migration in response to
sensitizer application in skin
Although TGFb1 alone altered homeostasis of dDC subsets,
it can also suppress the action of other inflammatory signals.
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Figure 2. Increase in plasmacytoid dendritic cells (DCs) and dermal DCs
(dDCs) in the dermis following transforming growth factor beta-1
(TGFb1) induction. Single transgenic (ST) and double transgenic (DT) mice
were given doxycycline (Dox) chow for 2 and 4 days, and dermal cells
prepared from mouse ears following separation of the epidermis and dermis.
Percentage of MHCIIhi cells (a) and different dDC subsets of the total
dermal cells were analyzed by flow cytometry at day 2 (b) and day 4 (c)
of TGFb1 induction. Error bars¼ ±SEM.
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To determine whether elevated epidermal TGFb1 altered
DBP-induced DC migration, mice were given Dox chow and
1% TRITC in a 1:1 mixture of acetone, and DBP was applied
to the shaved abdominal skin 18–24 hours later. At both 24
and 72 hours post TRITC/DBP treatment, TGFb1 overexpres-
sion significantly enhanced the total number of TRITCþ
MHCIIhi cells in SDLNs (Figure 5a). At 24 hours, migration
of TRITCþ CD207CD11b dDC, which constituted the
majority of TRITCþ DCs in SDLNs, was enhanced by TGFb1.
At 72 hours, LCs that migrate slower than other DC subsets
(Kissenpfennig et al., 2005) were the largest subpopulation of
TRITCþ cells in both groups, and overexpression of TGFb1
enhanced DBP-induced LC migration by 1.77-fold. In
addition, TGFb1 expression also caused a two-fold increase
in CD207CD11bþ dDC and a three-fold increase in
CD207CD11b dDC numbers at the 72-hour time point
(Figure 5a). A small number of TRITCþB220þ pDCs were
detected at 24 and 72 hours post TRITC, although their
numbers did not change significantly following TGFb1
induction. In addition, there was no effect at any time point
on TRITCþCD207þCD103þ dDC migration to SDLNs.
These results show that, under inflammatory conditions
induced by DBP application, TGFb1 differentially increases
numbers of CD207CD103 dDCs and LCs in SDLNs.
Elevated endogenous and exogenous TGFb1 increases migration
of LCs in vitro
To further evaluate the effects of elevated keratinocyte
TGFb1 on LC migration, we used skin explant cultures, an
inflammatory setting that causes DC migration (Stoitzner
et al., 1999). Explants from single transgenic (ST) and DT
mice placed on Dox chow for 24 hours were cultured, and
migrated skin DCs were analyzed after 48 hours of culture.
Under these conditions, 60–70% of DCs that migrated out
of the skin were LCs, and TGFb1 induction in vivo caused
a two-fold increase in their migration in vitro (Figure 5b).
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In addition, TGFb1 caused a 1.5-fold increase in migration
of the CD207CD11b dDC subset that represented 10% of
the migrated DC population. The increase in migration
correlated with the formation of numerous well-organized
dermal cords containing DCs in TGFb1-overexpressing
samples as opposed to scattered DCs and fewer dermal
cords in ST dermis following 48 hours of skin culture
(Figure 5c). Similarly, treatment of ear explant cultures from
FVB/n mice with exogenous TGFb1 stimulated LC migration
(Figure 5d) to nearly the same extent as the DC chemokine
CCL21 (Kissenpfennig et al., 2005) (Supplementary Figure S2
online).
Elevated keratinocyte TGFb1 promotes skin CHS
As the overexpression of TGFb1 in the epidermis enhanced
migration of DCs in response to topical application of the
contact sensitizer, we hypothesized that TGFb1 might affect
CHS responses. We induced TGFb1 expression using a one-
time intraperitoneal injection of Dox 18–24 hours before
sensitization with 0.5% DNFB. TGFb1 expression caused
a significant increase in the number of CD4þCD44þ
CD62Lþ central memory T cells and CD4þ IFNgþ cells
in SDLNs compared with ST mice (Figure 6a and b) following
5 days of sensitization. When mice sensitized in the presence
of TGFb1 were challenged with 0.3% DNFB, there was a
1.4-fold increase in ear thickness and weight (Figure 6c
and d). These results show that the alteration of skin DC
homeostasis by elevated keratinocyte TGFb1 results in
enhanced CHS responses.
DISCUSSION
DCs constantly migrate from peripheral tissues to draining
LNs in steady state at low frequencies and generally promote
tolerance and maintain tissue homeostasis (Steinman et al.,
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Figure 5. Elevated transforming growth factor beta-1 (TGFb1) enhances Langerhans cell migration following tetramethyl rhodamine iso-thiocyanate
(TRITC)/dibutylpthalate (DBP) treatment in vivo and in skin explant cultures in vitro. Double transgenic (DT) mice were given doxycycline (Dox) chow
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2000; Hawiger et al., 2001; Waithman et al., 2007).
Peripheral inflammation from infection, injury, and auto-
immunity can increase the rate of DC migration and numbers
in draining LNs and sustain T-cell activation (Ohl et al., 2004;
Coquerelle and Moser, 2010). Compared with steady state,
TGFb1 overexpression in keratinocytes caused profound
changes in composition and increased the numbers of skin-
derived dDC subsets and B220þ pDCs in the SDLNs. The
striking resemblance of these TGFb1-induced changes to
those occurring 24 hours following application of skin irritant
DBP suggests that increased TGFb1 and DBP alter the skin
microenvironment in a similar way. However, direct effects
of TGFb1 on DCs promoting their migration cannot be
ruled out.
TGFb1 induction also increased DBP-driven migration of
CD207CD11b and CD207CD11bþ dDC subsets.
Although we did not observe TGFb1-induced mobilization
of LCs, TGFb1 expression significantly enhanced DBP-
induced LC numbers in SDLNs. Consistent with this, ear
explant cultures, which mimic an inflammatory environment,
from TGFb1-induced mice had a two-fold increase in LC
migration, and LC numbers were comparable between skin
explant cultures treated with either exogenous TGFb1 or
the CCR7 ligand, CCL21. Thus, within the context of an
inflammatory microenvironment such as that established by
DBP or explant culture, elevated TGFb1 stimulates LC
migration rather than inhibiting it. It is not clear whether this
is mediated by effects of TGFb1 on LCs within the context of
other proinflammatory cytokines, or by indirect activation
mediated by TGFb1-induced upregulation of proinflamma-
tory cytokines along with other changes in the tissue
microenvironment. The lack of inhibition of LC homeostatic
trafficking to the LNs by elevated keratinocyte TGFb1
contrasts with studies showing that TGFb1 type-I receptor
ablation in LCs provokes LC maturation and migration (Kel
et al., 2010; Zahner et al., 2011). These differences suggest
that elevated keratinocyte-derived TGFb1 and LC TGFb1
signaling may have distinct effects on LC maturation and
migration.
Although activated DCs express elevated levels of the
costimulatory molecule CD86 before LN migration (Ban-
chereau and Steinman, 1998), we observed no significant
change in CD86 expression in dDCs except for the
CD207CD11b dDC subset. It is possible that coexistence
of migrating DCs with higher CD86 and influx of precursors
with less CD86 expression results in no apparent change in
the mean CD86 levels. However, the CD86 expression was
higher in all DC subsets in SDLNs as early as 2 days post
TGFb1 induction and remained high through 4 days.
Whether this results from the influence of CD207CD11b
dDCs on CD86 levels in other migratory DC population
or simply that other dDC subsets increase CD86 levels
en route to SDLNs remains to be determined. Further analysis
of other markers of migration and maturation such as CCR7
and E-cadherin (Kel et al., 2010; Zahner et al., 2011) will also
clarify the differential migration of dDCs versus LCs in
response to TGFb1.
The pDCs participate in antiviral immune responses and
may have an important role in the pathogenesis of
autoimmune diseases such as psoriasis and lupus (Gilliet
et al., 2008). The pDCs infiltrate the skin after wounding, in
tumors, in psoriasis, and following imiquimod application
(Palamara et al., 2004; Gilliet et al., 2008; Nestle et al., 2009;
Gregorio et al., 2010). Here we report for the first time that
TGFb1 overexpression causes a rapid increase in pDCs in the
dermis. The lack of proliferation in these cells suggests that
the increase is due to direct infiltration rather than expansion
of a skin-resident population. Although pDCs infiltrating skin
during psoriasis or lupus may be activated by complexes of
the antimicrobial peptide, LL37, produced by neutrophils,
and self-DNA from apoptotic cells in a Toll-like receptor
9–dependent manner (Nestle et al., 2009; Guiducci et al.,
2010), it remains to be determined whether this pathway of
pDC activation occurs in this mouse model. We have
previously reported induction of apoptosis in primary
keratinocytes cultured in excess TGFb1, as well as in telogen
follicles of DT mice upon TGFb1 induction (Liu et al., 2001),
suggesting that nucleic acids from the apoptotic cells could
trigger Toll-like receptor 7/9–mediated pDC activation. As
pDCs did not migrate in significant numbers following hapten
application in TGFb1-induced mice, it appears that increased
pDCs in the skin of TGFb1-overexpressing mice might
modulate or support local activation and maturation of
myeloid DCs as in psoriasis (Gilliet et al., 2008). Similar
to pDCs, we also noticed increases in percentages of
CD207þ dDCs and CD207CD11bþ dDCs but not the
CD207CD11b dDCs following 4 days of induction. As
the predominant dDC subset migrating in response to
TGFb1 induction was CD207CD11b (11-fold at 4 days),
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Figure 6. Transforming growth factor beta-1 induction during sensitization
enhances contact hypersensitivity response to DNFB (2,4-dinitro
fluorobenzene). Single transgenic (ST) and double transgenic (DT) mice
were injected with 500 ng doxycycline (Dox) per mouse 18–24 hours before
sensitization with 0.5% DNFB. Skin-draining lymph nodes (LNs) were
harvested 5 days post sensitization and analyzed for CD4 central memory
cells (a) and CD4þ IFNgþ cells (b) by flow cytometry (N¼ 2–3). Error
bars¼±SEM. Alternatively, mice were challenged on both sides of the
ear at day 5 using 0.3% DNFB and ears thickness (c) and ear weight (d)
analyzed 24 hours post challenge.
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it appears that a balance is maintained between infiltrating/
proliferating and migrating CD207CD11b dDC subset.
LCs constantly renew in the epidermis throughout life
(Merad et al., 2002), and dDCs are maintained by local
proliferation with some infiltration of blood-derived precursors
in steady state (Bogunovic et al., 2006). Because of increased
migration of dDC subsets to SDLNs at 4 days of TGFb1
induction, we predicted an increase in self-renewal potential to
maintain their normal homeostatic percentages in the dermis.
Despite increases in dermal percentages of most DC subsets,
proliferation only occurred in CD207þ and CD207CD11b
dDC subsets. Hence, it appears that TGFb1 alters dDC
homeostasis by promoting influx of blood-derived pDCs and
non-self-renewing DC precursors in the dermis while also
influencing proliferation of CD207þCD103þ dDCs and
CD207CD11b dDCs. The absence of any increases in
dermal percentage of CD207CD11b cells may reflect the
large and rapid migration of this subset to the SDLNs.
Our results highlight the potential proinflammatory role of
TGFb1 in skin immunity and show that TGFb1 overexpres-
sion by keratinocytes alters DC homeostasis and enhances
adaptive immunity in the context of CHS, although the DC
subset that mediates this response has not been determined.
Nevertheless, the effects of TGFb1 on dDC migration, pDC
influx, and enhanced CHS provide insight into the onset of
psoriasis-like skin inflammation following chronic TGFb1
induction in keratinocytes (Li et al., 2004), and suggest that
elevated TGFb1 in human psoriasis and other conditions of
elevated cutaneous TGFb1 may directly impact DC home-
ostasis, activation, and T-cell immunity.
MATERIALS AND METHODS
Mice
ST K14rTA or tetoTGFb1 and DT K14rTA-tetoTGFb1 mice in FVB/n
background that were sex- and age-matched (7–10 week) were
used for all the experiments. To induce keratinocyte TGFb1, DT
mice were given 1 g kg1 Dox chow (Bio-serve, Frenchtown, NJ).
Animals were treated according to approved Institutional Animal
Care and Use protocols.
Antibodies
The following antibodies were purchased from Ebioscience, San
Diego, CA: anti-CD16/32 (93), APC eFluor 750-anti-CD45 (30-F11),
FITC- and eFluor 450-anti-MHCII (M5/114.15.2), Alexa 700-anti-
CD11c (N418), FITC-anti-CD4 (GK1.5), PECy5-anti-CD8a (53-6.7),
PE-anti-CD103 (2E7), PECy7-anti-B220 (RA3-6B2), PE-anti-PDCA-1
(eBio-927), PercpCy5.5-anti-CD11b (M1/70), eFluor 450-anti-F4/80
(BM8), PE-anti-CD62L (MEL-14), and PECy5-anti-CD44 (IM7). The
following antibodies were purchased from BD Pharmingen, San
Diego, CA: PE-anti-CD45 (30-F11), Alexa 700-anti-CD86 (GL1), and
PECy7-anti-IFNg (XMG1.2). FITC-anti-BrdU (ABFM18) was purchased
from Phoenix Flow Systems, San Diego, CA. Alexa 568-anti-Epcam
(G8.8) and Alexa 647-anti-CD207 (L31) antibody conjugates were
generated as previously described (Gaiser et al., 2012).
Isolation and flow cytometric analysis of DC
Inguinal lymph nodes were gently disrupted using forceps and
incubated in Hank’s balanced salt solution containing 0.1%
collagenase D (Roche, Nutley, NJ) and 0.05% DNase I (Sigma,
St Louis, MO) for 30minutes at 37 1C. Epidermal and dermal cell
suspensions were prepared as described previously, with slight
modification (Nagao et al., 2009). Dermal components were cut into
small pieces and incubated for 45minutes in 0.1% collagenase D
and 0.05% DNase I for 45minutes at 37 1C, filtered using a 70-mm
cell strainer, and suspended in flow cytometry staining buffer. Single
cells were incubated with panels of monoclonal antibodies
following CD16/32 preincubation. For anti-CD207 staining, cells
were fixed and permeabilized using Foxp3 fixation/permeabilization
buffers (Ebioscience) and incubated with anti-langerin antibody in 0.2%
saponin buffer. Cells were acquired on BD Fortessa LSRII flow cyto-
meter and analyzed using the FlowJo software (Tree Star, Ashland, OR).
Analysis of cell proliferation
Mice were initially injected with 1mg BrdU in sterile phosphate-
buffered saline and then continuously given 0.8mgml1 BrdU in
drinking water, which was changed daily. Alternatively, 1mg BrdU
was injected intraperitoneally daily. Single cells were prepared from
inguinal LNs, epidermis, and dermis as described above, and were
first stained for surface markers and CD207. BrdU staining was
performed using the BrdU labeling flow kit (BD Pharmingen)
following the manufacturer’s protocol.
Skin explant cultures
Ears of ST and DT mice previously treated with Dox chow for
18–24hours were excised, rinsed in 70% ethanol, and then in a
solution containing 200 IUml1 penicillin and 200mgml1 strepto-
mycin for 5minutes. Ear skin was split into dorsal and ventral halves,
and at least four split ears were cultured in complete RPMI media,
10% fetal calf serum for 48 hours at 37 1C. FVB/n mouse ears were
cultured as described above and treated with either 100 ngml1
CCL21 (R&D systems, Minneapolis, MN) or 500 pgml1 TGFb1
(R&D systems). The migratory cells from the explant were harvested,
enumerated, and analyzed by flow cytometry.
Epidermal and dermal sheet immunofluorescence
Epidermal and dermal sheets were prepared as described previously
(Nagao et al., 2009). For staining, dermal sheets were rehydrated in
phosphate-buffered saline and incubated overnight with FITC-anti-
MHCII antibody at 4 1C. Slides were mounted with Vectashield mount-
ing medium (Vector Laboratories, Burlingame, CA) and analyzed on an
Olympus BX61 microscope (Olympus America, Center Valley, PA).
TRITC painting
ST and DT mice were kept on 1 g kg1 Dox chow 18–24 hours before
treatment with 1% TRITC (Invitrogen, Eugene, OR) in 1:1 solution of
acetone and DBP on shaved abdominal skin. After 24 and 72 hours
post TRITC application, inguinal LNs were harvested and single cells
prepared as described above. Total viable cells per LN were counted
and stained for specific markers and analyzed by flow cytometry.
Contact hypersensitivity
ST and DT mice were injected intraperitoneally with 500 ng Dox
18–24hours before sensitization with 25 ml of 0.5% DNFB (Sigma) in
4:1 solution of acetone/olive oil on shaved abdominal skin. Mice
were challenged 5 days later with 20 ml of 0.3% DNFB on both sides
of the right ear. The left ear was treated with vehicle and served as a
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control for baseline thickness. Measurements of ear thickness (minus
baseline thickness), weight, and histological analysis were taken
24 hours following challenge, in a blinded manner.
Statistical analysis
All statistical analyses were performed using the GraphPad Prism
software (GraphPad Software, La Jolla, CA). A two-tailed Student’s t-
test was performed to compare the groups. Under certain
circumstances where the variances were significant, a Mann–Whit-
ney test was performed.
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